Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research
Chair, Taofeek K. Owonikoko, MD, PhD, Carl M. Gay, MD, PhD, and Ticiana Leal, MD, prepared useful Practice Aids pertaining to small cell lung cancer for this CME/MOC/NCPD/AAPA activity titled “Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at https://bit.ly/3pijZiM. CME/MOC/NCPD/AAPA credit will be available until July 4, 2024.
Chair and Presenter Taofeek K. Owonikoko, MD, PhD, Hossein Borghaei, DO, MS, and Anne Chiang, MD, PhD, FASCO, prepared useful Practice Aids pertaining to small cell lung cancer for this CME/MOC/AAPA activity titled “Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/46zyU93. CME/MOC/AAPA credit will be available until January 2, 2025.
Co-Chairs and Presenter Jessica Donington, MD, Jonathan D. Spicer, MD, PhD, FRCSC, and Patrick M. Forde, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC/AAPA activity titled “A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3MQVu5l. CME/MOC/CC/AAPA credit will be available until February 27, 2025.
Chair, Jamie E. Chaft, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC/NCPD activity titled “Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC.” For the full presentation, downloadable Practice Aids and complete CME/MOC/CC/NCPD information, and to apply for credit, please visit us at https://bit.ly/3fcc3qs. CME/MOC/CC/NCPD credit will be available until July 11, 2022.
Jorge A. Marrero, MD, MS, Anthony El-Khoueiry, MD, Richard S. Finn, MD, and Laura M. Kulik, MD, prepared useful practice aids pertaining to HCC management for this CME activity titled "Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2Pj9wM8. CME credit will be available until December 20, 2019.
Chair, Jessica Donington, MD, David H. Harpole Jr., MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/AAPA activity titled “Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC: Leveraging Science, Enhancing Collaboration, and Improving Outcomes With Neoadjuvant and/or Adjuvant Checkpoint Inhibition.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3OtwGAh. CME/MOC/AAPA credit will be available until October 22, 2024.
Chair, David M. O'Malley, MD, Ana Oaknin, MD, PhD, and Matthew A. Powell, MD, prepared useful Practice Aids pertaining to endometrial cancer for this CME/MOC/AAPA activity titled “Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evidence Into Meaningful Improvements in Patient Outcomes Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/40bmalK. CME/MOC/AAPA credit will be available until July 3, 2024.
Chair and Moderator, Petros Grivas, MD, PhD, Shilpa Gupta, MD, and Gary D. Steinberg, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC activity titled “Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2WcJp3n. CME/MOC credit will be available until December 31, 2022.
Edward B. Garon, MD, MS, Jamie E. Chaft, MD, and Matthew D. Hellmann, MD, prepared useful Practice Aids pertaining to lung cancer management for this CME/MOC/CE activity titled "Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice." For the full presentation, monograph, complete CME/MOC/CE information, and to apply for credit, please visit us at http://bit.ly/2ATq0qp. CME/MOC/CE credit will be available until November 21, 2019.
Chair and Presenter Taofeek K. Owonikoko, MD, PhD, Hossein Borghaei, DO, MS, and Anne Chiang, MD, PhD, FASCO, prepared useful Practice Aids pertaining to small cell lung cancer for this CME/MOC/AAPA activity titled “Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/46zyU93. CME/MOC/AAPA credit will be available until January 2, 2025.
Co-Chairs and Presenter Jessica Donington, MD, Jonathan D. Spicer, MD, PhD, FRCSC, and Patrick M. Forde, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC/AAPA activity titled “A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3MQVu5l. CME/MOC/CC/AAPA credit will be available until February 27, 2025.
Chair, Jamie E. Chaft, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC/NCPD activity titled “Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC.” For the full presentation, downloadable Practice Aids and complete CME/MOC/CC/NCPD information, and to apply for credit, please visit us at https://bit.ly/3fcc3qs. CME/MOC/CC/NCPD credit will be available until July 11, 2022.
Jorge A. Marrero, MD, MS, Anthony El-Khoueiry, MD, Richard S. Finn, MD, and Laura M. Kulik, MD, prepared useful practice aids pertaining to HCC management for this CME activity titled "Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2Pj9wM8. CME credit will be available until December 20, 2019.
Chair, Jessica Donington, MD, David H. Harpole Jr., MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/AAPA activity titled “Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC: Leveraging Science, Enhancing Collaboration, and Improving Outcomes With Neoadjuvant and/or Adjuvant Checkpoint Inhibition.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3OtwGAh. CME/MOC/AAPA credit will be available until October 22, 2024.
Chair, David M. O'Malley, MD, Ana Oaknin, MD, PhD, and Matthew A. Powell, MD, prepared useful Practice Aids pertaining to endometrial cancer for this CME/MOC/AAPA activity titled “Endometrial Cancer Care in the Age of Immunotherapy: Translating Clinical Evidence Into Meaningful Improvements in Patient Outcomes Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/40bmalK. CME/MOC/AAPA credit will be available until July 3, 2024.
Chair and Moderator, Petros Grivas, MD, PhD, Shilpa Gupta, MD, and Gary D. Steinberg, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC activity titled “Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2WcJp3n. CME/MOC credit will be available until December 31, 2022.
Edward B. Garon, MD, MS, Jamie E. Chaft, MD, and Matthew D. Hellmann, MD, prepared useful Practice Aids pertaining to lung cancer management for this CME/MOC/CE activity titled "Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice." For the full presentation, monograph, complete CME/MOC/CE information, and to apply for credit, please visit us at http://bit.ly/2ATq0qp. CME/MOC/CE credit will be available until November 21, 2019.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Chair and Presenters Kathleen N. Moore, MD, MS, Floor J. Backes, MD, and Bhavana Pothuri, MD, MS, prepared useful Practice Aids pertaining to endometrial cancer for this CME/MOC/NCPD/AAPA/IPCE activity titled “Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3SjJyuH. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 17, 2025.
Chair and Presenter Neal D. Shore, MD, FACS, Sia Daneshmand, MD, and Guru P. Sonpavde, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/AAPA activity titled “Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/40qGkJH. CME/MOC/AAPA credit will be available until December 28, 2024.
Roy H. Decker, MD, PhD, and Sarah B. Goldberg, MD, MPH, prepared useful practice aids pertaining to lung cancer for this CME activity titled "The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2PU3iaZ. CME credit will be available until December 6, 2019.
Richard S. Finn, MD, Anthony El-Khoueiry, MD, and Josep M. Llovet, MD, PhD, prepared useful practice aids pertaining to hepatocellular carcinoma for this CME activity titled "Breaking the Paradox: Expanding Options and New Questions in HCC Management: Mapping the Pathways to Better Patient Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2HU6L5K. CME credit will be available until February 14, 2020.
Its INC initiates to educate with services of all nurse working in clinical case management of AIDS, Malaria, Filaria, Tuberculosis,other leading infectoious diseases to prevent and control aspect of health of individual/community/society.
GFATM for nurses The Global Fund provides 30% of all international financing for HIV programs and has invested US$24.2 billion in programs to prevent and treat HIV and AIDS and US$5 billion in TB/HIV programs as of June 2022.12- make more awareness for nursinfg officer
Evan J. Lipson, MD, Andrew Stolbach, MD, MPH, and Trish Brothers, BSN, RN, OCN®, prepared useful practice aids pertaining to oncologic emergencies for this CME/MOC/CNE/CPE activity titled "Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED." For the full presentation, monograph, complete CME/MOC/CNE/CPE information, and to apply for credit, please visit us at http://bit.ly/2TGpnYl. CME/MOC/CNE/CPE credit will be available until February 21, 2020.
Recurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive Carei3 Health
i3 Health is pleased to make this slide deck from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck, presented by Glenn J. Hanna, MD, Director, Center for Cancer Therapeutic Innovation (Early Drug Development Program)
Medical Oncologist, Center for Head & Neck Oncology
Dana-Farber Cancer Institute, and Deborah Wong, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, UCLA Medical Center, was presented at a live educational event at the 2024 Multidisciplinary Head and Neck Cancers Symposium. It will provide expert perspectives on harnessing immunotherapy in recurrent/metastatic HNSCC to provide comprehensive care.
Co-Chairs Riad Salem, MD, MBA, and Mark Yarchoan, MD, discuss liver cancer in this CME/MOC activity titled “Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3IOQvQ6. CME/MOC credit will be available until June 14, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, prepared useful Practice Aids pertaining to non-cystic fibrosis bronchiectasis for this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
More Related Content
Similar to Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Chair and Presenters Kathleen N. Moore, MD, MS, Floor J. Backes, MD, and Bhavana Pothuri, MD, MS, prepared useful Practice Aids pertaining to endometrial cancer for this CME/MOC/NCPD/AAPA/IPCE activity titled “Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3SjJyuH. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 17, 2025.
Chair and Presenter Neal D. Shore, MD, FACS, Sia Daneshmand, MD, and Guru P. Sonpavde, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/AAPA activity titled “Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/40qGkJH. CME/MOC/AAPA credit will be available until December 28, 2024.
Roy H. Decker, MD, PhD, and Sarah B. Goldberg, MD, MPH, prepared useful practice aids pertaining to lung cancer for this CME activity titled "The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2PU3iaZ. CME credit will be available until December 6, 2019.
Richard S. Finn, MD, Anthony El-Khoueiry, MD, and Josep M. Llovet, MD, PhD, prepared useful practice aids pertaining to hepatocellular carcinoma for this CME activity titled "Breaking the Paradox: Expanding Options and New Questions in HCC Management: Mapping the Pathways to Better Patient Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2HU6L5K. CME credit will be available until February 14, 2020.
Its INC initiates to educate with services of all nurse working in clinical case management of AIDS, Malaria, Filaria, Tuberculosis,other leading infectoious diseases to prevent and control aspect of health of individual/community/society.
GFATM for nurses The Global Fund provides 30% of all international financing for HIV programs and has invested US$24.2 billion in programs to prevent and treat HIV and AIDS and US$5 billion in TB/HIV programs as of June 2022.12- make more awareness for nursinfg officer
Evan J. Lipson, MD, Andrew Stolbach, MD, MPH, and Trish Brothers, BSN, RN, OCN®, prepared useful practice aids pertaining to oncologic emergencies for this CME/MOC/CNE/CPE activity titled "Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED." For the full presentation, monograph, complete CME/MOC/CNE/CPE information, and to apply for credit, please visit us at http://bit.ly/2TGpnYl. CME/MOC/CNE/CPE credit will be available until February 21, 2020.
Recurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive Carei3 Health
i3 Health is pleased to make this slide deck from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck, presented by Glenn J. Hanna, MD, Director, Center for Cancer Therapeutic Innovation (Early Drug Development Program)
Medical Oncologist, Center for Head & Neck Oncology
Dana-Farber Cancer Institute, and Deborah Wong, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, UCLA Medical Center, was presented at a live educational event at the 2024 Multidisciplinary Head and Neck Cancers Symposium. It will provide expert perspectives on harnessing immunotherapy in recurrent/metastatic HNSCC to provide comprehensive care.
Similar to Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research (20)
Co-Chairs Riad Salem, MD, MBA, and Mark Yarchoan, MD, discuss liver cancer in this CME/MOC activity titled “Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3IOQvQ6. CME/MOC credit will be available until June 14, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, prepared useful Practice Aids pertaining to non-cystic fibrosis bronchiectasis for this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, discuss non-cystic fibrosis bronchiectasis in this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Jonathan E. McConathy, MD, PhD, and Gil Rabinovici, MD, discuss Alzheimer's disease in this CME/AAPA activity titled “Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheimer’s Disease: Preparing Nuclear Medicine and Radiology Specialists for New Diagnostic Workflows.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/45RFl6g. CME/AAPA credit will be available until June 15, 2025.
Co-Chairs Sarah Hayward, PharmD, BCOP, and Ambar Khan, PharmD, BCOP, discuss endometrial and cervical cancers in this CME/CPE/IPCE activity titled “A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care.” For the full presentation, downloadable Practice Aids, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at https://bit.ly/3wGBPQp. CME/CPE/IPCE credit will be available until May 27, 2025.
Co-Chairs, Suzanne Lentzsch, MD, PhD, and Joshua Richter, MD, discuss multiple myeloma in this CME activity titled “‘Four-Ward’ Progress in NDMM: New Developments With CD38 Antibody Quadruplets.” For the full presentation and complete CME information, and to apply for credit, please visit us at https://bit.ly/3x3oWA3. CME credit will be available until May 23, 2025.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, discuss lung cancer in this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Chair Oliver Sartor, MD, discusses prostate cancer in this CME activity titled “On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic Strategies in Prostate Cancer.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/49oY4IJ. CME credit will be available until May 23, 2025.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Chair, Nicholas J. Short, MD, discusses acute lymphoblastic leukemia in this CME/NCPD/CPE/AAPA/IPCE activity titled “Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies & MRD-Guided Strategies Across Disease Settings.” For the full presentation, downloadable Practice Aids, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/42QsTDT. CME/NCPD/CPE/AAPA/IPCE credit will be available until May 22, 2025.
Chair, Sharon Cohen, MD, FRCPC, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
Chair, Sharon Cohen, MD, FRCPC, discusses Alzheimer’s disease in this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
Chair and Presenter, Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, Donna D. Catamero, ANP-BC, OCN, CCRC, and Charise Gleason, MSN, NP-C, AOCNP, discuss multiple myeloma in this CME/MOC/NCPD/ILNA/IPCE activity titled “Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/47mtUnM. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.
Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.
Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, discuss NSCLC in this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.
Co-Chairs, Sia Daneshmand, MD, and Matthew D. Galsky, MD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Strategies for Integrating the Latest Evidence and Treatment Advances.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3OOeYbO. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 13, 2025.
Chair Jamie Carroll, APRN, CNP, MSN, discusses breast cancer in this NCPD/ILNA/AAPA activity titled “Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education.” For the full presentation, downloadable Practice Aids, and complete NCPD/ILNA/AAPA information, and to apply for credit, please visit us at https://bit.ly/3SdnvWt. NCPD/ILNA/AAPA credit will be available until May 8, 2025.
Chair Jonathan A. Bernstein, MD, discusses chronic spontaneous urticaria in this CME activity titled “BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3P0cnvi. CME credit will be available until May 6, 2025.
Co-Chairs Milind Desai, MD, MBA, FACC, FAHA, FESC, and Andrew Willeford, PharmD, PhD, BCCP, prepared useful Practice Aids pertaining to hypertrophic cardiomyopathy for this CME/MOC/CPE/AAPA/IPCE activity titled “Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/4bb7eKc. CME/MOC/CPE/AAPA/IPCE credit will be available until May 16, 2025.
More from PVI, PeerView Institute for Medical Education (20)
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research
1. SCLC Treatment Algorithm1-3
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/WFE40
1. Created by Aakash Desai, MBBS, MPH. Used with permission from the author. 2. Paz-Ares L et al. ESMO Open. 2022;7:100408.3. Paz-Ares LG et al. ESMO 2021. Abstract LBA61.
CT abdomen/pelvis, PET/CT scan (if needed), MRI brain, PFTs,
bone marrow biopsy (select cases), mediastinal staging (stage I-IIA)
Stage and Workup
Cancer confined to one hemithorax and regional lymph nodes (can be treated with single radiation field)?
!"#"$%&'($)*%
?#*@*&#($2,'$+'(%+3(-+$,2$0"'%+*)($*-+(-+
Limited-Stage Disease
Eligible for treatment of curative intent
%4$%5("6%'($)*%
Extensive-Stage Disease
Stage III/IV disease; not eligible for treatment of curative intent
YES NO
STAGE I-IIA
STAGE IIB-IIIC
Pathologic
mediastinal
staging
Positive
Negative
Platinum-based
chemotherapy
+
concurrent RT
JCOG 9104:
Concurrent RT vs
sequential RT
• mOS: 27.2
vs 19.7 mo
• HR, 0.70
Lobectomy +
mediastinal LN dissection
Platinum-based
chemotherapy
Platinum-based
chemotherapy
+
mediastinal RT
pT1-2,
N0-1,
R0
N2
and/or
R1-2
Take into account PS, comorbidities, and age
Meta-analysis: PCI vs no PCI
RR of death HR, 0.84 (P = .01)
Prophylactic Cranial Irradiation in Patients Achieving Remission (ALL Stages)
PS ≤1 or ≥2 due to SCLC
PS ≥2 due to
comorbidities
BSC in consult
with palliative
medicine
1L: Chemo-immunotherapy
If ineligible for
immunotherapy,
use platinum-
based
chemotherapy
>6 mo treatment-
free interval?
Relapse
Yes No
2L: Chemotherapy
2L: Chemotherapy
Carboplatin + etoposide + atezolizumab
with maintenance atezolizumab
IMpower133: Chemo + atezo vs chemo
• mOS: 12.3 vs 10.3 mo
• HR, 0.70
Carboplatin or cisplatin + etoposide +
durvalumab with maintenance durvalumab
CASPIAN: Chemo + durva vs chemo
• mOS: 12.9 vs 10.5 mo
• HR, 0.71
Rechallenge with original
platinum-based
chemotherapy (preferred)
Lurbinectedin
PMB1183-B005014: Single arm
• ORR: 35%
• mDOR: 5.1 mo
CAV
Lurbinectedin (preferred)
PMB1183-B005014: Single arm
• ORR: 35%
• mDOR: 5.1 mo
Topotecan (preferred)
Trial: Topotecan vs CAV
• ORR: 23.3% vs 18.3%
Clinical trials (preferred)
CAV
cT1-2, N0, M0
T1-2, N1, M0
T3-4, Nx, M0
2. The Immunotherapy Era in SCLC: Approved Treatments
and Immune-Related Adverse Event Management
Full abbreviations, accreditation, and disclosure information available at PeerView.com/WFE40
Currently Approved PD-L1–Blocking Antibodies in Immuno-Chemotherapies, Supporting Evidence, and Practical Guidance
Durvalumab1,2
Granted FDA approval in
combination with
etoposide and either
carboplatin or cisplatin as
first-line treatment of
patients with ES-SCLC
on March 27, 2020
Indicated in combination with etoposide and either
carboplatin or cisplatin as first-line treatment of
adult patients with ES-SCLC
Indication
1,500 mg every 3 weeks prior to chemotherapy
in combination with etoposide and either carboplatin
or cisplatin, then every 4 weeks as a single agent
Dosing2
CASPIAN: A Randomized, Controlled, Open-Label, Phase 3 Trial3-6
Most Common AEs
(All Grades)1
• Nausea (34%)
• Fatigue/asthenia (32%)
• Alopecia (31%)
Atezolizumab7,8
Granted FDA approval in
combination with
carboplatin and
etoposide for first-line
treatment of adult
patients with ES-SCLC
on March 18, 2019
Indicated in combination with carboplatin and etoposide
for first-line treatment of adult patients with ES-SCLC
Indication
1,200 mg every 3 weeks prior to chemotherapy with
carboplatin and etoposide; 840 mg every 2 weeks,
1,200 mg every 3 weeks, or 1,680 mg every 4 weeks following
completion of 4 cycles of carboplatin and etoposide
Dosing7
IMpower33: A Double-Blind, Placebo-Controlled, Phase 3 Trial9
Most Common AEs
(All Grades)7
"
• Fatigue/asthenia
• Nausea
• Alopecia
• Constipation
• Diarrhea
• Decreased appetite
Platinum-etoposide
(n = 269)
Durvalumab +
Platinum-etoposide
(n = 268)
156 (58)
182 (68)
5.1 (4.8-5.3)
5.1 (4.9-5.3)
Median duration of
response,
mo (95% CI)
10.5 (9.3-11.2)
12.9 (11.3-14.7)
Median OS,
mo (95% CI)
5.4 (4.8-6.2)
5.1 (4.7-6.2)
Median PFS,
mo (95% CI)
a
Objective response by investigator review per RECIST 1.1 is defined as patients with complete
response or partial response on at least one visit (unconfirmed responses); for confirmed
responses, a confirmatory scan was required ≥4 weeks after the initial response.
Placebo
(n = 202)
Atezolizumab
(n = 201)
130 (64.4)
121 (60.2)
3.9 (2.0-16.1)
4.2 (1.4-19.5)
Median duration of
response,
mo (range)c
Confirmed objective
response, n (%)a
Confirmed objective
response, n (%)b
10.3 (9.3-11.3)
12.3 (10.8-15.9)
Median OS,
mo (95% CI)
4.3 (4.2-4.5)
5.2 (4.4-5.6)
Median PFS,
mo (95% CI)
b
Assessed in patients in the ITT population who had measurable disease at baseline. Defined
as confirmed complete response or partial response by investigator review per RECIST 1.1.
c
Assessed in patients who had a confirmed objective response. Defined as the time from first
occurrence of a documented objective response to the time of disease progression as
determined by the investigator (according to RECIST) or death from any cause, whichever
occurred first.
3. The Immunotherapy Era in SCLC: Approved Treatments
and Immune-Related Adverse Event Management
Full abbreviations, accreditation, and disclosure information available at PeerView.com/WFE40
What Are irAEs?1
• Immune checkpoint inhibitors are associated with important clinical benefits, but general immunologic enhancement
can also lead to a unique spectrum of immune-related adverse events
• Any organ system can be affected, but more commonly occurring are pulmonary (pneumonitis), dermatologic (rash, pruritus,
blisters, ulcers, vitiligo), gastrointestinal (diarrhea, enterocolitis, transaminitis, hepatitis, pancreatitis), and endocrine
(thyroiditis, hypophysitis, adrenal insufficiency) irAEs
Endocrine
Hyper- or hypothyroidism
Hypophysitis
Adrenal insufficiency
Diabetes
Hepatic
Hepatitis
Renal
Nephritis
Dermatologic
Rash
Pruritus
Psoriasis
Vitiligo
DRESS
Stevens-Johnson
Hematologic
Hemolytic anemia
Thrombocytopenia
Neutropenia
Hemophilia
Ocular
Uveitis
Conjunctivitis
Scleritis, episcleritis
Blepharitis
Retinitis
Respiratory
Pneumonitis
Pleuritis
Sarcoid-like granulomatosis
Cardiovascular
Myocarditis
Pericarditis
Vasculitis
Gastrointestinal
Colitis
Ileitis
Pancreatitis
Gastritis
Neurologic
Neuropathy
Guillain Barré
Myelopathy
Encephalitis
Myasthenia
Musculoskeletal
Arthritis
Dermatomyositis
Immune-Related Adverse Events (irAEs)10
4. General Recommendations for Treating irAEs11-14
Increasing
Intensity
of
Treatment
Required
Increasing Grade of irAE
Managed in Outpatient/Community Setting Generally Requires Hospital Admission
Steroids (PO/IV): 1-2 mg/kg/d
prednisone or equivalent, slowly
taper over 4-6 weeks
For some AEs, treatment can be
restarted after resolution (eg, rash);
generally, ICI can be continued with
endocrinopathies once managed
Grade 2
Grade 1 Grade 3 Grade 4
Moderate
Mild Severe Very Severe
Symptomatic & supportive therapy
Stop treatment
Oral steroids Intravenous steroids. ------------>
• Referral to specialist
• Strong immune-suppressive treatment
intravenous steroids
The Immunotherapy Era in SCLC: Approved Treatments
and Immune-Related Adverse Event Management
Full abbreviations, accreditation, and disclosure information available at PeerView.com/WFE40
5. The Immunotherapy Era in SCLC: Approved Treatments
and Immune-Related Adverse Event Management
Full abbreviations, accreditation, and disclosure information available at PeerView.com/WFE40
Hold immunotherapy and reassess in 1-2 weeks
Pulse oximetry rest and ambulation
Consider chest imaging with CT (with contrast preferred)
Repeat in 3-4 weeks
Moderate (grade 2): 25%-50%
lung involved
Severe (grade 3-4)
Grade 3: all lobes of lung or
>50% of lung parenchyma;
limited ADLs, oxygen requirement
Grade 4: life threatening
Hold immunotherapy
Infectious workup (nasal swab, sputum, blood)
Consider bronchoscopy and BAL
Chest imaging with CT contrast
Repeat in 3-4 weeks
Consider empiric antibiotics
Refractory: methylprednisolone 1-2 mg/m2
/day; if no response in 3-4 days, treat as grade 3
Permanently discontinue immunotherapy and move to inpatient care
Infectious workup (nasal swab, sputum, blood)
Pulmonary and infectious disease consultation
Bronchoscopy with BAL
Empiric antibiotics
Methylprednisolone 1-2 mg/m2
/day; when grade 1, taper over 6 weeks
Refractory: infliximab, mycophenolate, or IVIG
How Should Pulmonary irAEs Be Diagnosed and Managed?11,15
Pneumonitis: focal or diffuse inflammation of the lung parenchyma (typically identified on CT imaging)
Diagnostic workup: CXR, CT, pulse oximetry; for grade ≥2, may include infectious workup
Mild (grade 1): <25% lung
involved
Additional considerations
• GI and pneumocystis prophylaxis may be offered to patients on prolonged steroid use (>12 weeks)
• Consider calcium and vitamin D supplementation with prolonged steroid use
• Bronchoscopy and biopsy; if clinical picture is consistent with pneumonitis, no need for biopsy
Supportive care: smoking cessation and vaccinations (influenza, pneumococcal)
6. The Immunotherapy Era in SCLC: Approved Treatments
and Immune-Related Adverse Event Management
Full abbreviations, accreditation, and disclosure information available at PeerView.com/WFE40
1. Imfinzi (durvalumab) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s033lbl.pdf. 2. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-extensive-stage-small-cell-lung-cancer.
3. Paz-Ares L et al. Lancet. 2019;394:1929-1939. 4. Goldman JW et al. Lancet Oncol. 2021;22:51-65. 5. Paz-Ares L et al. ESMO Open. 2022;7:100408. 6. Paz-Ares LG et al. ESMO 2021. Abstract LBA61. 7. Tecentriq (atezolizumab) Prescribing Information. https://www.accessdata.fda.gov/
drugsatfda_docs/label/2023/761034s049s051lbl.pdf. 8. https://www.fda.gov/drugs/drug-approvalsand-databases/fda-approves-atezolizumab-extensive-stage-small-cell-lung-cancer. 9. Horn L et al. N Engl J Med. 2018;379:2220-2229. 10. Champiat S et al. Ann Oncol. 2016;27:559-
574. 11. Brahmer JR et al. J Clin Oncol. 2018;36:1714-1786. 12. https://www.esmo.org/content/download/124130/2352601/1/ESMO-Patient-Guide-on-Immunotherapy-Side-Effects.pdf. 13. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf.
14. Puzanov I et al. J Immunother Cancer. 2017;5:95. 15. Provided courtesy of Marianne Davies, DNP, ACNP, AOCNP, FAAN, 2021; adapted from AIM with Immunotherapy, NCCN, and CTCAE. 16. https://ascopubs.org/doi/full/10.1200/JCO.21.01440.
17. https://www.esmo.org/content/download/124130/2352601/1/ESMO-Patient-Guide-on-Immunotherapy-Side-Effects.pdf. 18. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf.
19. https://www.sitcancer.org/research/cancer-immunotherapy-guidelines/irae/immune-checkpoint-inhibitor-related-adverse-events.
Additional Guideline Recommendations for Treating irAEs16-19
7. Lurbinectedin: The Newest FDA-Approved
Second-Line Treatment Option in SCLC
Full abbreviations, accreditation, and disclosure information available at PeerView.com/WFE40
Lurbinectedin (Selective Inhibitor of Oncogenic Transcription)1,2
Granted accelerated
FDA approval
on June 15, 2020
based on overall
response rate and
duration of response
Indicated for the treatment of adult patients with
metastatic SCLC with disease progression on or
after platinum-based chemotherapy
Indication
3.2 mg/m2
via intravenous infusion every 21 d
(consider premedication with corticosteroids
and serotonin antagonists)
Dosing2
Mechanism of Action1
• Category 2A other recommended regimen following first-line platinum-based
chemotherapy
• For patients with ECOG PS 0-2 (consider dose reduction or growth factor support
for patients with ECOG PS 2)
NCCN Guidelines: Second-Line and Beyond Therapy3
ORR by Investigator Assessment1
Most Common Grade 3/4 AEs1
Other common adverse events include lymphopenia, fatigue, increased creatinine, increased
alanine aminotransferase, increased glucose, nausea, decreased appetite, musculoskeletal
pain, decreased albumin, constipation, dyspnea, decreased sodium, increased aspartate
aminotransferase, vomiting, cough, decreased magnesium, and diarrhea
Neutropenia
46%
Anemia
9%
Leukopenia
29%
Thrombocytopenia
7%
All patients
35.2%
Chemotherapy-free
interval ≥90 d
45.0%
Chemotherapy-free
interval <90 d
22.2%
Tumor
CCL2
Induction of
apoptosis
Monocyte
CCL2
CXCL8
VEGF
Reduced
cancer-related
inflammation
TAM
Inhibition of
cell migration
LURBINECTEDIN
• Synthetically produced
agent, originally
derived from
Ecteinascidia turbinata
• A selective inhibitor of
oncogenic transcription
1. Zepzelca (lurbinectedin) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213702s004lbl.pdf. 2. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer.
3. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.
8. LUNGevity Foundation: Small Cell Lung Cancer
Resource Compendium
Full abbreviations, accreditation, and disclosure information available at PeerView.com/WFE40
The following pages include information for patients with lung cancer for use as a printable resource
lungevity.org
Through research, advocacy, and community, LUNGevity is transforming
what it means to be diagnosed and live with lung cancer
www.lungevity.org/order-materials
LUNGevity educational materials order form for providers:
.
9. LUNGevity Foundation: Small Cell Lung Cancer
Resource Compendium
1 What Is Small Cell Lung Cancer (SCLC)? The Stages of SCLC
• Lung cancer staging describes where the cancer is located,
if and where it has spread, and whether it is affecting other
parts of the body
• Treatments are available for every stage
Extensive-stage: cancer has spread more widely throughout the
lung, to the other lung, to lymph nodes on the other side of the
chest, or to distant organs
Limited-stage: cancer is only in one side of the chest: one lung,
the tissues between the lungs, and nearby lymph nodes only
Most commonly used system: 2 stages
3
2
4
Diagnosis of SCLC Treatment Options
Many different tests are used to diagnose SCLC, including
• Biopsies: tests in which small
amounts of tissue are removed
for examination to find out if a
person has lung cancer and, if
so, which type
• Imaging: tests that create
pictures of the inside of the
body by x-rays, magnetic
fields, sound waves, or
radioactive particles
Currently approved treatment options for SCLC include:
• Surgery
• Radiation therapy
• Chemotherapy
• Immunotherapy
In addition, several new types of treatment are being studied
for SCLC. These are available through clinical trials.
https://sclc.lungevity.org/sclc/about-small-cell-lung-cancer
• SCLC is one of the two major types of lung cancer
• It accounts for about 15% of all lung cancers
• It is most often found in people with
a smoking history
• SCLC derives its name from
the way the cancer cells look
under a microscope
Trachea
Bronchoscope
or endoscope
Throat
Lymph nodes
Lung
Bronchi
Small cell
lung cancer
(cells under
microscope)
10. Booklets: www.LUNGevity.org/booklets
In booklet 1, you will learn
• What SCLC is
• What lung cancer staging is
• The stages of SCLC
What is small cell lung
cancer (SCLC)?
One-Page Fact Sheets
In booklet 2, you will learn
• Types of tests doctors do to find SCLC
• What happens during imaging tests
• Why doctors do biopsies and what happens
during them
• Other ways doctors learn about your health
In booklet 3, you will learn
• How you and your doctor will decide on a treatment plan
• What the treatment options are for SCLC
• Common side effects of treatment
Comprehensive
booklet
Questions to ask your
doctor to better
understand SCLC, stage,
and treatment options
Resources and support
for SCLC
2
Educational Materials and Supporting Resources
The Small Cell Lung Cancer Patient Gateway is a tailored portal for people with SCLC to learn more about
treatment for SCLC, connect to experts and SCLC patient communities, and access educational resources
Find a Specialist Find a Clinical Trial Blog and Forum
Find Your Community
3
1
2
LUNGevity Foundation: Small Cell Lung Cancer
Resource Compendium